



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**15.12.2021 Bulletin 2021/50**

(45) Date of publication and mention  
of the grant of the patent:  
**10.11.2021 Bulletin 2021/45**

(21) Application number: **13820038.1**

(22) Date of filing: **18.07.2013**

(51) Int Cl.:  
**C07D 513/04** <sup>(2006.01)</sup> **C07D 498/04** <sup>(2006.01)</sup>  
**C07D 487/04** <sup>(2006.01)</sup> **C07D 407/12** <sup>(2006.01)</sup>  
**C07D 413/12** <sup>(2006.01)</sup> **A61K 31/429** <sup>(2006.01)</sup>  
**A61K 31/4188** <sup>(2006.01)</sup> **A61K 31/4427** <sup>(2006.01)</sup>  
**A61K 31/5377** <sup>(2006.01)</sup> **A61P 31/04** <sup>(2006.01)</sup>  
**A61P 31/06** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/US2013/051125**

(87) International publication number:  
**WO 2014/015167 (23.01.2014 Gazette 2014/04)**

(54) **5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS**

5,5-HETEROAROMATISCHE INFEKTIONSHEMMENDE VERBINDUNGEN

COMPOSÉS ANTI-INFECTIEUX 5,5-HÉTÉROAROMATIQUES

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **18.07.2012 US 201261672968 P**

(43) Date of publication of application:  
**27.05.2015 Bulletin 2015/22**

(73) Proprietor: **University of Notre Dame du Lac**  
**South Bend, IN 46617 (US)**

(72) Inventors:  
• **MORASKI, Garrett**  
**Bozeman**  
**Montana 59715 (US)**  
• **MILLER, Marvin J.**  
**South Bend**  
**Indiana 46635 (US)**

(74) Representative: **FRKelly**  
**27 Clyde Road**  
**Dublin D04 F838 (IE)**

(56) References cited:  
**WO-A1-95/29922 WO-A1-2009/147431**

**WO-A1-2011/073316 WO-A2-2008/020405**  
**WO-A2-2008/038251 WO-A2-2008/081399**  
**WO-A2-2008/087611 WO-A2-2009/016560**

- **O DELL L R ET AL: "Functionalized 3-amino-imidazo[1,2-a]pyridines: A novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 19, no. 16, 15 August 2009 (2009-08-15), pages 4790-4793, XP026419080, ISSN: 0960-894X [retrieved on 2009-06-14]**
- **TERZIOGLU, NALAN ET AL.: 'Synthesis and anticancer evaluation of some new hydrazone derivatives of 2,6-dimethylimidazo[2,1-b][1,3,4]thiadiazol e-5-carbohydrazide.' EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY vol. 38, 2003, pages 781 - 786, XP004448330 & ABIGNENTE E. ET AL.: 'Research on heterocyclic compounds. XVIII. Imidazo[2,1-b]- 1,3,4-thiadiazole derivatives.' IL FARMACO, EDIZIONE SCIENTIFICA vol. 40, no. 3, 1984, pages 190 - 199, XP055182683**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- SYOICHI, BAN ET AL.: 'Studies on chemotherapeutics. XXXIX. Synthesis of imidazo compounds. IV. Imidazo[2,1-b]thiadiazole derivatives.' YAKUGAKU ZASSHI vol. 74, no. 2, 1954, pages 658 - 661, XP055182683
- Victoria J. Compton ET AL: "Reaction of 2-aminothiazoles with reagents containing a C-halogen and a CO electrophilic centre", Journal of the Chemical Society, Perkin Transactions 1, no. 15, 1 January 1992 (1992-01-01), pages 2029-2032, XP055350996, GB ISSN: 0300-922X, DOI: 10.1039/P19920002029